Hospitals and health systems enter 2025 facing familiar pressure: tighter budgets, higher patient expectations, and supply chains still recovering from the shocks of recent years. That combination makes supply chain strategy less about lean ideals and more about keeping care safe, predictable, and affordable. When the right product isn’t where and when clinicians need it, the result is stress for staff, delays for patients, and avoidable costs for the organization.
This article is a practical playbook for leaders who want three things at once: resilience when disruptions hit, smarter use of data to plan and predict, and stronger alignment with the clinicians who actually deliver care. We’ll walk through the measurable goals every program should own, how to protect the items that matter most to patients, the data and AI moves that make planning realistic, and ways to get clinician buy‑in without sacrificing outcomes.
Along the way you’ll find concrete measures — from stockout rates and days on hand to procedure‑level supply costs and scope‑3 emissions — and tactical approaches like dual sourcing for critical SKUs, UDI capture at point of use, and clinician‑centered value analysis. If you lead supply chain, procurement, clinical operations, or simply want fewer surprises in the OR and clinic, this guide will help you prioritize the changes that deliver impact in 2025.
Keep reading to see the eight metrics to own, the resilience playbook for the highest‑risk items, the data architecture that finally connects ERP to EHR, and practical steps to make clinicians partners in cost and quality improvement.
Define success: the 8 metrics every healthcare supply chain strategy should own
A modern healthcare supply chain needs clear, clinician‑relevant metrics that tie procurement and logistics to patient safety, cost control, and sustainability. These eight measures should be owned by the supply chain function, tracked in near‑real time, and reported to clinical, financial, and quality leaders so decisions are fast, accountable, and auditable.
Stockout rate for critical supplies (never events = 0)
What to track: percentage of patient‑impacting stockouts for items deemed “critical” (blood products, critical implants, emergency meds, sterile OR consumables). Define a catalog of critical SKUs with clinical owners and require immediate escalation for any event.
Why it matters: stockouts directly threaten patient safety and drive emergency purchases, case delays, and clinician frustration. Treat any stockout for a critical SKU as a near‑miss or never‑event and investigate root cause, corrective actions, and process gaps.
Fill rate and on‑time delivery by supplier and category
What to track: supplier fill rate (orders delivered as requested) and on‑time delivery performance segmented by category and lead time band. Capture both supplier performance and distributor performance where applicable.
Why it matters: consistent fill and on‑time performance reduce the need for costly expedited orders and temporary substitutions. Use these metrics to drive supplier scorecards, procurement decisions, and contractual SLAs tied to remedies or incentives.
Days on hand and inventory turns by site and service line
What to track: days on hand and inventory turns calculated per hospital site, clinic, OR, and key service lines (e.g., cath lab, OR, infusion). Combine with case schedule and demand signals to spot imbalances.
Why it matters: too much stock ties up capital and increases obsolescence risk; too little raises service risk. Segment targets by criticality and volatility rather than applying a single rule across the enterprise.
Expired and obsolete write‑offs as a percent of spend
What to track: write‑offs for expiry, product obsolescence, and damage expressed as a share of total supply spend and broken down by category and supplier.
Why it matters: this metric highlights inventory governance breakdowns, poor demand forecasting, and SKU proliferation. Drive improvement through clean item masters, minimum order quantities aligned to consumption, and clinician review for low‑use SKUs.
Spend under contract and price variance to benchmark
What to track: percent of spend governed by negotiated contracts or approved sourcing channels, plus variance of paid price versus internal benchmarks or market indexes by category.
Why it matters: visibility into contracted coverage and price leakage protects margins and reduces maverick buying. Use this metric to prioritize renegotiations, compliance programs, and adoption of preferred agreements within clinical workflows.
Supplier risk tiers and dual‑sourcing coverage for Tier‑1/2
What to track: a supplier risk matrix that scores suppliers on strategic criticality, single‑source exposure, geographic concentration, and financial/operational resilience. Track the percent of Tier‑1 and Tier‑2 SKUs that have qualified second‑source options or validated clinical substitutions.
Why it matters: knowing which suppliers would cause the largest operational disruption allows targeted mitigation—dual sourcing, safety stock, or alternate routing—rather than blanket measures that inflate inventory and cost.
Procedure‑level supply cost linked to outcomes and LOS
What to track: true procedure cost of consumables and implants aggregated to the case level and linked to clinical outcomes and length of stay (LOS). Combine device and supply use with outcomes data to identify high‑value versus low‑value variation.
Why it matters: clinicians decide device use at the bedside; showing procedure‑level cost alongside outcomes creates the basis for value analysis, formulary decisions, and gainsharing models that preserve quality while reducing unnecessary variability.
Scope 3 emissions per bed‑day/procedure (decarbonization lens)
What to track: supplier‑attributed Scope 3 emissions normalized to operational units (per bed‑day, per procedure) for major categories (devices, disposables, transport). Use supplier data, emissions factors, and spend mapping to estimate the footprint.
Why it matters: sustainability goals increasingly influence procurement strategy, contract terms, and public reporting. Tracking emissions on an activity basis makes tradeoffs explicit—cost, quality, and carbon—and enables targeted supplier engagement and low‑carbon substitutions.
Operationalize ownership by assigning each metric to a cross‑functional steward (supply chain, clinical ops, finance, quality), defining data sources (ERP, EHR, inventory systems, supplier reports), and publishing a short set of dashboard KPIs for weekly and executive review. With these measures in place you can move from measurement to prioritized action — focusing investments, sourcing changes, and inventory buffers where they will protect patients and preserve value.
Resilience first: segment, dual‑source, and buffer what matters
Resilience is not about hoarding everything—it’s about making smart choices on what to protect, how to protect it, and when to lean on alternatives. The following five practices create a practical playbook: tier SKU criticality by patient risk, secure multiple supply routes where exposure is highest, set dynamic buffers for true risk, prepare clinician‑approved substitutions and playbooks, and test third‑party resilience continuously.
Criticality tiering (A/B/C) tied to patient risk and care pathways
Start with a clinical‑led SKU segmentation: A items are patient‑impacting (no acceptable delay or substitution), B items support care continuity (substitutable with lead time), C items are low‑risk or administrative. Map each SKU to the care pathways and scenarios where it matters most—emergency, OR, ICU, ambulatory procedures.
Implementation steps: assemble clinician owners for each category, document clinical impact and acceptable recovery times, and assign clear stocking and sourcing rules per tier. Review tiers quarterly and after any incident to keep the model aligned with clinical practice.
Dual/multi‑sourcing and regionalization for vulnerable SKUs
For A and key B items, require at least two qualified sources and prefer geographic diversity to reduce single‑point failures. For high‑volume or strategic categories, build a mix of national distributors, direct manufacturer contracts, and vetted regional suppliers to shorten emergency fulfillment.
Practical guardrails: define qualification criteria (quality, lead time, financial viability), embed dual‑source requirements into category strategies, and use contracting to protect availability (e.g., minimum fill commitments, visibility to capacity constraints).
Dynamic safety stocks and PAR min/max for high‑risk items
Replace one‑size‑fits‑all buffers with demand‑driven safety stock. Use clinical schedules and historical consumption patterns to set PAR levels for ORs, clinics, and satellite sites, and make adjustments for seasonality, supplier lead‑time variability, and known events.
Keep buffers under active governance: automate reorders where possible, flag manual approvals for outliers, and align inventory targets with financial and quality owners so safety stock balances service and cost objectives.
Backorder playbooks and clinically approved substitution lists
Create standardized playbooks that specify escalation steps, communication templates, and substitution hierarchies when items are delayed. Every substitution should be pre‑approved by clinical leadership or follow a rapid clinical review process so patient care isn’t compromised at the bedside.
Elements to include: triggering conditions for each playbook, authorized substitutes with usage guidance, billing and documentation changes, and a post‑event review to capture lessons and update formularies or contracts.
Third‑party risk: cyber, business continuity, and disaster drills
Supply chain resilience extends to supplier systems and services. Require third‑party risk assessments that include cyber posture, recovery time objectives, and contingency plans. Contractually mandate minimum BC capabilities and notification obligations for disruptions.
Operationalize resilience with regular tabletop exercises and live drills that involve suppliers, procurement, clinical teams, and IT. Use scenarios that combine cyber incidents, transport failures, and demand surges to validate playbooks and uncover latent dependencies.
Make these levers repeatable: assign owners, embed metrics into category scorecards, and build a short incident lifecycle (detect → escalate → substitute → learn). That operational foundation sets the stage for the data and systems work that transforms these policies into predictable performance and automated decisioning.
Make data your edge: unify item data, integrate ERP–EHR, and apply AI planning
Data is the operational advantage that turns policies into predictable performance. Start by fixing the basics—clean item data and capture at point of use—then connect systems, mirror clinical rhythms in planning, and apply forecasting and simulation so the supply chain responds proactively instead of reactively.
Clean item master and UDI capture at point of use
Establish a single source of truth for every SKU with normalized attributes (description, pack, unit of measure, manufacturer, GTIN/UDI). Require barcode/UDI scanning at receipt and point of use so consumption flows into analytics reliably and charge capture and recalls are automated.
Quick wins: resolve duplicates, retire low‑value SKUs, require manufacturer provenance on new additions, and assign clinical owners who approve any item master changes.
Real‑time inventory visibility across PARs, ORs, and clinics
Operational visibility means knowing what is on every shelf and rotor in near‑real time. Integrate smart cabinets, dispenser telemetry, and mobile scanning into a unified inventory layer so replenishment, expiries, and usage variances are surfaced to planners and clinicians.
Use role‑based dashboards: frontline staff see replenishment queues; supply chain sees enterprise‑level stock positions and exceptions for action.
S&OP that mirrors block schedules, seasonality, and campaigns
Standard S&OP must adapt to clinical cadence. Align supply planning with OR block schedules, anticipated procedure volumes, seasonal demand (e.g., respiratory waves), and elective care campaigns so procurement, inventory, and logistics reflect clinical reality rather than static forecasts.
Embed simple rules: link high‑impact case schedules to priority replenishment, surface manual approvals for schedule changes, and run weekly cadence calls that include surgical and clinical operations.
AI forecasting and what‑if simulation
Layer probabilistic forecasting and scenario simulation on clean data to anticipate shortages, optimize safety stock, and evaluate sourcing or schedule changes before they happen. Combine demand signals (EHR case data), supplier lead times, and risk tiers to generate recommended actions.
“AI-driven inventory and planning tools have been shown to reduce supply chain disruptions by ~40% and lower supply chain costs by ~25% — with related implementations also delivering roughly 20% lower inventory costs and ~30% less product obsolescence.” Life Sciences Industry Challenges & AI-Powered Solutions — D-LAB research
Run regular what‑if drills (supplier outage, demand surge, transport delay) in the model and publish prioritized playbooks so the organization executes faster when a real disruption occurs.
Automate 3‑way match, bill‑only implants, recall matching, and charge capture
Free capacity and reduce leakage by automating transactional workflows: three‑way PO/invoice/receipt matching, implant bill‑only workflows tied to case records, automated recall matching against implant registries, and charge capture integrated with the EHR. Automation reduces errors and speeds reimbursement while improving auditability.
Start with the highest‑value categories and iterate—automation projects succeed fastest when item identifiers and clinical links are already clean.
Ownership and governance matter: assign data stewards, publish SLA‑backed data quality targets, and make data quality a procurement KPI. When your systems and models produce credible, clinician‑facing insights, you can shift conversations from anecdote to evidence and unlock the clinical partnerships that preserve both care and cost.
Thank you for reading Diligize’s blog!
Are you looking for strategic advise?
Subscribe to our newsletter!
Win clinician buy‑in: value analysis that standardizes without hurting outcomes
Standardization only works when clinicians trust the process. Value analysis should be collaborative, transparent, and evidence‑driven: show how choices affect outcomes, cost, and workflow; give clinicians the data and the trial design to validate changes; and build incentives and nudges that align clinical autonomy with system goals.
Physician Preference Item governance with head‑to‑head trials and registries
Treat physician preference items (PPIs) as clinical decisions, not procurement wins. Create a formal governance forum that includes surgeons, nurses, supply chain, and outcomes analysts. For contested items, run head‑to‑head trials with defined endpoints (clinical outcomes, procedure time, complication rates, and supply cost).
Use device registries or short‑term observational studies to collect real‑world evidence. Prioritize rapid, pragmatic trials that fit into clinical workflows and agree upfront on non‑inferiority margins so clinicians see the tradeoffs clearly.
Procedure dashboards: cost, outcomes, variation, and device utilization
Give clinicians case‑level transparency. Dashboards should show supply cost per procedure, key outcomes (complications, readmissions, LOS), variation by operator, and device utilization rates—updated frequently and benchmarked internally. Visual, case‑level data turns abstract supply savings into clinician‑relevant insights.
Design dashboards for peer review and constructive discussion, not punishment: highlight best practices, enable drilldowns to device or SKU level, and surface opportunities for standardization where outcomes are equivalent but costs differ.
Gainsharing and formulary compliance embedded in contracts and EHR nudges
Align incentives through gainsharing programs that reward departments or clinicians for verified savings that do not harm outcomes. Embed formulary rules into contracts and operationalize compliance with gentle EHR nudges—order sets, default device choices, and pop‑ups that present cost and outcome tradeoffs at the point of decision.
Keep incentives transparent and clinically governed: savings should be reinvested in clinical priorities (training, equipment, staffing) so clinicians see direct benefit from participation.
OR case cart optimization and implant traceability into the EHR and revenue cycle
Optimize case carts and OR par levels to reduce waste and excess while ensuring clinicians have what they need. Standardize kits where possible, use surgeon‑approved templates, and implement barcode/UDI capture for implants so traceability, recall response, and charge capture are automatic.
Integrate implant data into the EHR and the revenue cycle to prevent lost charges and to support outcome tracking tied to specific devices. When clinicians know devices are traceable and outcomes are linked, they are more comfortable with standardization that preserves clinical choice.
Operational success depends on governance: nominate clinical champions, create rapid‑cycle pilots, define measurable endpoints, and agree a post‑pilot roll‑out path. When clinicians contribute to trial design and see peer‑validated results, standardization becomes a clinical quality effort rather than a cost exercise—setting up smoother conversations about sourcing, supplier performance, and sustainable procurement strategies that follow next.
Smarter sourcing and sustainability: contracts that cut cost and carbon
Sourcing strategy in 2025 must simultaneously drive savings, service, and a shrinking carbon footprint. Contracts are the lever that aligns supplier behavior with clinical needs and sustainability goals: use blended sourcing, firm performance SLAs, inventory partnerships, product‑life interventions, and traceability clauses to lock in value.
Blend GPO leverage with targeted direct contracts for strategic categories
Keep broad categories on GPO agreements to capture scale while carving out high‑impact or strategic categories (implants, high‑use disposables, high‑risk reagents) for direct negotiation. Direct contracts allow clinical collaboration on specifications, tighter quality clauses, and bespoke pricing that reflect volume commitments and outcome expectations.
Design procurement playbooks that define when to use GPO, when to pursue direct sourcing, and how to route clinicians to preferred channels so savings are realized without adding friction at the point of care.
Performance‑based SLAs: fill rate, lead time, backorder penalties, and transparency
Move beyond price‑only contracts. Specify measurable SLAs—fill rate, on‑time delivery, lead‑time variability, accuracy—and include remedies (rebates, credits) or incentives tied to performance. Require real‑time reporting of inventory and lead‑time signals so your team can respond before service gaps occur.
Include transparency clauses that mandate visibility into supplier capacity and known constraints, plus regular business reviews with predefined escalation paths to resolve systemic issues quickly.
VMI/consignment and distributor data‑sharing for PPIs and implants
Use vendor‑managed inventory (VMI) or consignment for expensive, slow‑moving, or clinically critical SKUs to reduce capital tied in inventory while maintaining availability. Insist on electronic data sharing—consumption, on‑hand, and case schedule feeds—so replenishment is predictive rather than reactive.
Contractually define inventory ownership, billing triggers (e.g., point‑of‑use scan), reporting cadence, and performance KPIs to avoid disputes and ensure revenue capture and compliance.
Reprocessing, right‑sized packaging, and lower‑carbon suppliers and transport
Include sustainability options in RFPs and contracts: reprocessed device programs where clinically acceptable, reduced packaging or consolidated shipments, and preference for suppliers with verifiable lower‑carbon operations or greener logistics options. Build clauses that allow for pilot programs and phased adoption so clinical safety and efficacy are validated first.
Negotiate lifecycle cost assessments, not just unit price, so decisions reflect waste reduction, reprocessing costs, and disposal impacts as part of total cost of ownership.
DSCSA/UDI traceability that speeds recalls and reduces waste
Require DSCSA/UDI traceability capabilities in supplier contracts for regulated products and implants. Clauses should mandate unique device identifiers, timely transmission of traceability data, and responsibilities for recall notifications and replacement timing.
Traceability shortens recall response, reduces clinical risk, and limits unnecessary waste by enabling targeted removals instead of broad disposals—improving both patient safety and sustainability outcomes.
Operationalize these approaches with clear contract templates, supplier scorecards that include sustainability metrics, and a cross‑functional steering committee that connects procurement, clinical leaders, sustainability, and finance. When contracts codify performance, transparency, and environmental considerations, sourcing becomes a predictable engine for both cost reduction and lower carbon impact.